CD274 and lymphoma: Although no statistical analysis showed that high PD-L1 predicts a better treatment outcome, the manageable toxicity observed in these two clinical trials demonstrated that the PD-1 blockade could be considered as a salvage therapy strategy in other high PD-L1 expressing EBV-associated lymphomas.